Kevin Chow is a biotech entrepreneur and executive with over two decades of scientific and commercial experience, currently co-founding and leading Mitera Biosciences to reimagine immunotherapy for transplantation and autoimmune disease. He combines a Ph.D. in Microbiology and Immunology from UBC with a proven track record of advancing therapeutic programs from partner deals to acquisition, including founding Vitaeris and negotiating its strategic collaboration and eventual acquisition by CSL Behring. As President and COO of Incisive Genetics he is driving LNP delivery innovations for in vivo CRISPR therapies while maintaining active leadership roles across multiple venture-stage companies. Known for bridging deep scientific expertise with deal-making acumen, he has repeatedly translated academic technologies into clinical and commercial pathways. Based in Vancouver, he also engages with academic and community initiatives (see organization UBCMJC) that reflect his continued ties to research and mentorship.
12 years of coding experience
20 years of employment as a software developer
Ph.D. Microbiology and Immunology, Ph.D. Microbiology and Immunology at The University of British Columbia
Contributions:106 commits, 39 PRs, 184 pushes in 2 years 7 months
meteorgamesmahjongjavascriptleague
Find and Hire Top DevelopersWe’ve analyzed the programming source code of over 60 million software developers on GitHub and scored them by 50,000 skills. Sign-up on Prog,AI to search for software developers.
Request Free Trial
Kevin Chow - Co-founder, President & CEO at Incisive Genetics